Received Jan 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (VAQTA) | MERCK & CO. INC. | UNK | Y009094 | — |
No adverse event; an expired adult dose of VAQTA (1mL) was inadvertently administered to two patients less than 18 years of age who should have received a pediatric dose of VAQTA (0.5mL) on 12/29/2025; an expired adult dose of VAQTA (1mL) was inadvertently administered to two patients less than 18 years of age who should have received a pediatric dose of VAQTA (0.5mL) on 12/29/2025; This Spontaneous report was received from Other health professional and referred to an 11 -year-old Female patient. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. On 29-Dec-2025, the patient was vaccinated with Hepatitis A Vaccine, Inactivated, Adult, 50 u/mL Suspension for injection 64457223:4096 (1.00 mL) (total) (Batch/Lot Number: Y009094, which was confirmed to be valid) (Expiration date: 29-Nov-2025) Suspension for injection (Dose Text: 1mL/once) for prophylaxis. It was reported that an expired adult dose of VAQTA (1mL) was inadvertently administered to the patient, who was less than 18 years of age, who should have received a pediatric dose of VAQTA (0.5mL) (Expired vaccine used; Accidental overdose). The patient reported in this case did not report any adverse issues or side effects related to the administered dose of VAQTA and the product had never undergone any temperature excursions (No adverse event). This is one of two cases received from the same reporter (cross-referenced with case# 2366170).